InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: Carboat post# 199522

Friday, 12/12/2014 2:51:25 AM

Friday, December 12, 2014 2:51:25 AM

Post# of 346002
I disagree with what you say about management has its flaws? This is all about the science of PS Targeting and Bavituximab and I am amazed that you fail to ever mention the flaws that they were dealt in sabotage in Fargo and ...

Peregrine BOD's #1 job was to save that phase IIb NSCLC and avoid having to redo another phase II --- yes, job complete

Peregrines BOD's #1 job was then to initiate Phase III and prepare sites ---yes, job just about complete with over 150 clinical sites

Peregrines BOD's #1 job is now to keep all material event news off the radar and prepare for the launch of a lifetime ..stay tuned : )

I left out much like the two interim looks...etc..etc, too many puzzle pieces : )

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News